Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis

Gastroenterology

Volumn 146, Issue 7, 2014, Pages

  Mandorfer, Mattias ^a,b   Bota, Simona ^a,b   Schwabl, Philipp ^a,b   Bucsics, Theresa ^a,b   Pfisterer, Nikolaus ^a,b   Kruzik, Matthias ^a,b   Hagmann, Michael ^a   Blacky, Alexander ^c   Ferlitsch, Arnulf ^a,b   Sieghart, Wolfgang ^a,b   Trauner, Michael ^a,b   Peck Radosavljevic, Markus ^a,b   Reiberger, Thomas ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Vienna Hepatic Hemodynamic Lab   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adrenergic Receptor; Bacterial Infection; Liver Fibrosis; Mortality; Blocker

Indexed keywords

CARVEDILOL; PROPRANOLOL;

ACUTE KIDNEY FAILURE; ADULT; ARTERIAL PRESSURE; ARTICLE; ASCITES; BACTERIAL INFECTION; BACTERIAL PERITONITIS; FEMALE; HEPATORENAL SYNDROME; HOSPITALIZATION; HUMAN; KIDNEY BLOOD FLOW; LIVER CIRRHOSIS; LIVER GRAFT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; NONHUMAN; PARACENTESIS; PRIORITY JOURNAL; RAT; RETROSPECTIVE STUDY; SURVIVAL TIME; VARICOSIS;

ADRENERGIC RECEPTOR; BACTERIAL INFECTION; LIVER FIBROSIS; MORTALITY; Β BLOCKER;

PERITONITIS; ACUTE KIDNEY INJURY; ADRENERGIC BETA-ANTAGONISTS; AGED; AUSTRIA; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; HEMODYNAMICS; HEPATORENAL SYNDROME; HUMANS; HYPERTENSION, PORTAL; KAPLAN-MEIER ESTIMATE; LENGTH OF STAY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PARACENTESIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901228105     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.03.005     Document Type: Article

References (41)

1. M. Blachier, H. Leleu, and M. Peck-Radosavljevic et al. The burden of liver disease in Europe: a review of available epidemiological data J Hepatol 58 2013 593 608
2. S.K. Asrani, J.J. Larson, and B. Yawn et al. Underestimation of liver-related mortality in the United States Gastroenterology 145 2013 375 382 e1-2
3. G. D'Amico, G. Garcia-Tsao, and L. Pagliaro Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies J Hepatol 44 2006 217 231
4. P.S. Ge, and B.A. Runyon The changing role of beta-blocker therapy in patients with cirrhosis J Hepatol 60 2014 643 653
5. M. Peck-Radosavljevic, B. Angermayr, and C. Datz et al. Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II) Wien Klin Wochenschr 125 2013 200 219
6. R. de Franchis Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension J Hepatol 53 2010 762 768
7. G. Garcia-Tsao, A.J. Sanyal, and N.D. Grace et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis Hepatology 46 2007 922 938
8. D. Lebrec, T. Poynard, and P. Hillon et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study N Engl J Med 305 1981 1371 1374
9. V. Hernandez-Gea, C. Aracil, and A. Colomo et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with beta-blockers Am J Gastroenterol 107 2012 418 427
10. T. Reiberger, A. Ferlitsch, and B.A. Payer et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis J Hepatol 58 2013 911 921
11. M. Senzolo, E. Cholongitas, and P. Burra et al. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis Liver Int 29 2009 1189 1193
12. T. Serste, C. Melot, and C. Francoz et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites Hepatology 52 2010 1017 1022
13. A. Krag, R. Wiest, and A. Albillos et al. The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease Gut 61 2012 967 969
14. G. D'Amico, L. Pagliaro, and J. Bosch Pharmacological treatment of portal hypertension: an evidence-based approach Semin Liver Dis 19 1999 475 505
15. V. Arvaniti, G. D'Amico, and G. Fede et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis Gastroenterology 139 2010 1246 1256 1256 e1-5
16. A. Ferlitsch, J. Pleiner, and F. Mittermayer et al. Vasoconstrictor hyporeactivity can be reversed by antioxidants in patients with advanced alcoholic cirrhosis of the liver and ascites Crit Care Med 33 2005 2028 2033
17. P. Bellot, J.C. Garcia-Pagan, and R. Frances et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis Hepatology 52 2010 2044 2052
18. L. Ruiz-del-Arbol, J. Urman, and J. Fernandez et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis Hepatology 38 2003 1210 1218
19. A. Krag, F. Bendtsen, and J.H. Henriksen et al. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites Gut 59 2010 105 110
20. A. Krag, S. Moller, and A.K. Burroughs et al. Betablockers induce cardiac chronotropic incompetence J Hepatol 56 2012 298 299
21. F. Bendtsen, J.H. Henriksen, and T.I. Sorensen Propranolol and haemodynamic response in cirrhosis J Hepatol 13 1991 144 148
22. M. Ferlitsch, T. Reiberger, and M. Hoke et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis Hepatology 56 2012 1439 1447
23. P.S. Kamath, and W.R. Kim The model for end-stage liver disease (MELD) Hepatology 45 2007 797 805
24. C. Child, and J. Turcotte Surgery and portal hypertension C. Child, The Liver and Portal Hypertension 1964 Saunders Philadelphia 50 64
25. M. Peck-Radosavljevic, M. Trauner, and F. Schreiber Austrian consensus on the definition and treatment of portal hypertension and its complications Endoscopy 37 2005 667 673
26. European Association for the Study of the Liver EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis J Hepatol 53 2010 397 417
27. B.A. Runyon Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012 Hepatology 57 2013 1651 1653
28. C. Fagundes, R. Barreto, and M. Guevara et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis J Hepatol 59 2013 474 481
29. R.L. Mehta, J.A. Kellum, and S.V. Shah et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury Crit Care 11 2007 R31
30. F. Wong, and F. Salerno Beta-blockers in cirrhosis: friend and foe? Hepatology 52 2010 811 813
31. M. Kurt Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites Hepatology 53 2011 1411 1412
32. G.H. Lo Effects of beta-blockers on survival for patients with cirrhosis and refractory ascites Hepatology 53 2011 1068 1069
33. A. Agustin, and Z. Javier Beta-blockers in patients with cirrhosis and refractory ascites Hepatology 53 2011 1783
34. T. Serste, C. Francoz, and F. Durand et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study J Hepatol 55 2011 794 799
35. Robins A, Bowden A, Watson W, et al. Propranolol at modest doses does not impair survival in patients with cirrhosis and refractory ascites. Hepatology in press.
36. R. Banares, E. Moitinho, and A. Matilla et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis Hepatology 36 2002 1367 1373
37. T. Reiberger, G. Ulbrich, and A. Ferlitsch et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol Gut 62 2013 1634 1641
38. A. Galbois, V. Das, and D. Thabut et al. Beta-blockers have no effect on outcomes in patients with cirrhosis and severe infections Hepatology 53 2011 1412 1413
39. J. Llach, P. Gines, and V. Arroyo et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites Gastroenterology 94 1988 482 487
40. C. Efe, T. Purnak, and E. Ozaslan The deleterious effects of propranolol on patients with cirrhosis Hepatology 53 2011 371 372
41. A. Krag, F. Bendtsen, and S. Moller Does cardiac dysfunction explain deleterious effects of beta-blockers in cirrhosis and refractory ascites? Hepatology 53 2011 370 371